Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89,600,000
-
Total 13F shares
-
76,097,271
-
Share change
-
-5,633,199
-
Total reported value
-
$371,356,824
-
Put/Call ratio
-
118%
-
Price per share
-
$4.88
-
Number of holders
-
161
-
Value change
-
-$40,940,545
-
Number of buys
-
93
-
Number of sells
-
75
Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q2 2024
As of 30 Jun 2024 Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) had 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 76,097,271 shares of stock of the company.
Largest 10 holders included Alphabet Inc., BlackRock Inc., VANGUARD GROUP INC, T. Rowe Price Investment Management, Inc., MILLENNIUM MANAGEMENT LLC, STATE STREET CORP, Casdin Capital, LLC, ARK Investment Management LLC, Novo Holdings A/S, and ARCH Venture Management, LLC.
This table shows 161 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.